Card image cap
DCGI clears Covovax for 12-17 age group

US vaccine maker Novavax said on Tuesday that its COVID-19 vaccine in India, Covovax, has received emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years. The authorization is a global first for the age group for the vaccine, which is manufactured and marketed in India by Serum Institute of India. Novavax had last month announced that its vaccine was 80 percent effective against COVID-19 in a late-stage trial testing the shot in 2,247 teens aged 12 to 17 years.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment